These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

849 related items for PubMed ID: 27380877

  • 1. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S, Sudheendra HV, Pandian R, Ravindra DR, Siddappa G, R N, Chevour P, Ramachandran B, Sagar M, Jayaprakash A, Mehta A, Kekatpure V, Hedne N, Kuriakose MA, Suresh A.
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [Abstract] [Full Text] [Related]

  • 2. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
    Keysar SB, Le PN, Miller B, Jackson BC, Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, Padilla-Just N, Gomez K, Warnock E, Reisinger J, Arcaroli JJ, Messersmith WA, Wakefield LM, Gao D, Tan AC, Serracino H, Vasiliou V, Roop DR, Wang XJ, Jimeno A.
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
    [Abstract] [Full Text] [Related]

  • 3. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
    Bourguignon LY, Wong G, Earle C, Chen L.
    J Biol Chem; 2012 Sep 21; 287(39):32800-24. PubMed ID: 22847005
    [Abstract] [Full Text] [Related]

  • 4. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
    Basak SK, Zinabadi A, Wu AW, Venkatesan N, Duarte VM, Kang JJ, Dalgard CL, Srivastava M, Sarkar FH, Wang MB, Srivatsan ES.
    Oncotarget; 2015 Jul 30; 6(21):18504-17. PubMed ID: 26098778
    [Abstract] [Full Text] [Related]

  • 5. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
    Bourguignon LYW, Earle C, Shiina M.
    Int J Mol Sci; 2017 Aug 24; 18(9):. PubMed ID: 28837080
    [Abstract] [Full Text] [Related]

  • 6. Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.
    Subramanian C, Kovatch KJ, Sim MW, Wang G, Prince ME, Carey TE, Davis R, Blagg BSJ, Cohen MS.
    Neoplasia; 2017 Dec 24; 19(12):1003-1011. PubMed ID: 29121598
    [Abstract] [Full Text] [Related]

  • 7. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL, Zhao ZL, Liu JF, Ma SR, Huang CF, Liu B, Zhang WF, Sun ZJ.
    Oncotarget; 2015 Dec 08; 6(39):41944-58. PubMed ID: 26556875
    [Abstract] [Full Text] [Related]

  • 8. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Roy S, Roy S, Kar M, Padhi S, Saha A, Anuja K, Banerjee B.
    J Oral Pathol Med; 2018 May 08; 47(5):492-501. PubMed ID: 29575240
    [Abstract] [Full Text] [Related]

  • 9. Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma.
    Bourguignon LY, Wong G, Shiina M.
    J Biol Chem; 2016 May 13; 291(20):10571-85. PubMed ID: 27002147
    [Abstract] [Full Text] [Related]

  • 10. Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma.
    Bae WJ, Koo BS, Lee SH, Kim JM, Rho YS, Lim JY, Moon JH, Cho JH, Lim YC.
    Br J Cancer; 2017 Dec 05; 117(12):1810-1818. PubMed ID: 29096401
    [Abstract] [Full Text] [Related]

  • 11. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
    Lim YC, Kang HJ, Moon JH.
    Oral Oncol; 2014 Jul 05; 50(7):633-9. PubMed ID: 24835851
    [Abstract] [Full Text] [Related]

  • 12. Cancer stem cells enrichment with surface markers CD271 and CD44 in human head and neck squamous cell carcinomas.
    Elkashty OA, Abu Elghanam G, Su X, Liu Y, Chauvin PJ, Tran SD.
    Carcinogenesis; 2020 Jun 17; 41(4):458-466. PubMed ID: 31742606
    [Abstract] [Full Text] [Related]

  • 13. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer.
    Nör C, Zhang Z, Warner KA, Bernardi L, Visioli F, Helman JI, Roesler R, Nör JE.
    Neoplasia; 2014 Feb 17; 16(2):137-46. PubMed ID: 24709421
    [Abstract] [Full Text] [Related]

  • 14. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
    Roy S, Roy S, Kar M, Chakraborty A, Kumar A, Delogu F, Asthana S, Hande MP, Banerjee B.
    Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct 17; 846():503084. PubMed ID: 31585633
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
    Wang TY, Peng CY, Lee SS, Chou MY, Yu CC, Chang YC.
    Oncotarget; 2016 Dec 20; 7(51):84072-84081. PubMed ID: 27557511
    [Abstract] [Full Text] [Related]

  • 18. Slug is a novel molecular target for head and neck squamous cell carcinoma stem-like cells.
    Moon JH, Lee SH, Koo BS, Kim JM, Huang S, Cho JH, Eun YG, Shin HA, Lim YC.
    Oral Oncol; 2020 Dec 20; 111():104948. PubMed ID: 32771963
    [Abstract] [Full Text] [Related]

  • 19. Epigenetic modifications control loss of adhesion and aggressiveness of cancer stem cells derived from head and neck squamous cell carcinoma with intrinsic resistance to cisplatin.
    Milan TM, Eskenazi APE, Bighetti-Trevisan RL, de Almeida LO.
    Arch Oral Biol; 2022 Sep 20; 141():105468. PubMed ID: 35679799
    [Abstract] [Full Text] [Related]

  • 20. Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.
    Lee J, Park M, Ko Y, Kim B, Kim O, Hyun H, Kim D, Sohn H, Moon YL, Lim W.
    Tumour Biol; 2017 Apr 20; 39(4):1010428317695534. PubMed ID: 28381190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.